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The aim of this study was to establish antimicrobial susceptibility breakpoints for
tilmicosin against Haemophilus parasuis, which is an important pathogen of respiratory
tract infections. The minimum inhibitory concentrations (MICs) of 103 H. parasuis
isolates were determined by the agar dilution method. The wild type (WT) distribution
and epidemiologic cutoff value (ECV) were evaluated by statistical analysis. The new
bronchoaveolar lavage was used to establish intrapulmonary pharmacokinetic (PK)
model in swine. The pharmacokinetic (PK) parameters of tilmicosin, both in pulmonary
epithelial lining fluid (PELF) and in plasma, were determined using high performance
liquid chromatography method and WinNonlin software. The pharmacodynamic cutoff
(COPD) was calculated using Monte Carlo simulation. Our results showed that 100%
of WT isolates were covered when the ECV was set at 16 µg/mL. The tilmicosin
had concentration-dependent activity against H. parasuis. The PK data indicated that
tilmicosin concentrations in PELF was rapidly increased to high levels at 4 h and kept
stable until 48 h after drug administration, while the tilmicosin concentration in plasma
reached maximum levels at 4 h and continued to decrease during 4–72 h. Using Monte
Carlo simulation, COPD was defined as 1 µg/mL. Conclusively, the ECV and COPD
of tilmicosin against H. parasuis were established for the first time based on the MIC
distribution and PK-PD analysis in the target tissue, respectively. These values are
of great importance for detection of tilmicosin-resistant H. parasuis and for effective
treatment of clinical intrapulmonary infection caused by H. parasuis.
Keywords: epidemiologic cutoff value, pharmacodynamic cutoff, bronchoaveolar lavage, H. parasuis, tilmicosin
INTRODUCTION
Haemophilus parasuis, a Gram-negative bacterium of the Pasteurella group of organisms, is a
respiratory pathogens of pigs (Fu et al., 2013; Luan et al., 2013). It is mainly responsible for Glässer’s
disease, which is characterized by polyserositis, arthritis, and meningitis (Guo et al., 2011; Mullins
et al., 2013; Moleres et al., 2015) and has caused large economic losses in the worldwide pig industry
in recent years (Vilalta et al., 2012; Zehr et al., 2012).
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Tilmicosin is a macrolide antibiotic for veterinary use,
which is semi-synthesized by tylosin hydrolysate. Similar to
other macrolides, this drug has a long half-life and maintains
high concentrations both in lung and milk. Tilmicosin has
high-activity against respiratory pathogens such as Pasteurella
multocida, Actinobacillus pleuropneumoniae, and H. parasuis
(DeRosa et al., 2000). In addition, the antimicrobial activity of
tilmicosin is much better than that of tylosin (Ayling et al., 2000).
Therefore, tilmicosin has broad clinical application for treatment
of respiratory diseases in animals (Frank et al., 2000; Naccari et al.,
2001; Fittipaldi et al., 2005).
Establishing the antimicrobial susceptibility breakpoint sets
the basis for antimicrobial susceptibility testing and antimicrobial
resistance surveillance. Although breakpoints of tilmicosin
against P. multocida and A. pleuropneumoniae are available in
Clinical and Laboratory Standards Institute (CLSI) standards, a
breakpoint of tilmicosin against H. parasuis has not yet been
established.
An appropriate antimicrobial susceptibility breakpoint is
established by the interpretation of four main types of data
(Turnidge and Paterson, 2007): (i) MIC distributions; (ii)
resistance markers; (iii) PK/PD data of the target subjects;
(iv) clinical data of wild type (WT) isolates which has no
reported detectable resistance mechanisms (Turnidge et al.,
2006). The statistical analysis are used in setting breakpoints
(Turnidge et al., 2006; Kronvall, 2010; Meletiadis et al., 2012).
Without clinical data, an epidemiologic cutoff value (ECV)
could be used to discriminate WT strains from isolates with
resistance mechanisms (Espinel-Ingroff et al., 2010). However, a
susceptibility breakpoint solely based on ECV could not predict
the clinical outcome. In the absence of a clinical cutoff, the
Pharmacokinetic/Pharmacodynamic cutoff (COPD) is associated
with clinical efficacy, as both PK/PD data and WT distribution
are included for setting COPD.
The plasma concentration of the drug is responsible for
pharmacological effect. Several studies have shown that the
drug concentrations in the target sites were directly correlated
with clinical efficacy (Barbour et al., 2010). In addition,
bronchoaveolar lavage (BAL) has frequently been used to
establish an intrapulmonary PK model, especially for macrolides
(Conte et al., 2000b, 2004). In the case of animals, the
problem of long sampling intervals makes plasma concentrations
incomparable with pulmonary epithelial lining fluid (PELF)
concentrations (Villarino et al., 2013).
The purpose of this study was to establish the ECV and
COPD of tilmicosin against H. parasuis, in addition to an
intrapulmonary PK model of tilmicosin in pigs.
MATERIALS AND METHODS
Organisms
From March to May 2014, a total of 103 H. parasuis strains were
donated by State Key Laboratory of Agricultural Microbiology
at Huazhong Agricultural University and National Reference
Laboratory of Veterinary Drug Residues at South China
Agricultural University. These strains were isolated from the
lungs of swine in 10 provinces of China. All of the bacterial
isolates were confirmed by polymerase chain reaction (PCR).
Prior to testing, each isolate was subcultured at least twice on
tryptic soy agar (TSA) containing 5% fetal calf serum (FCS) and
10 µg/mL nicotinamide adenine dinucleotide (NAD) to ensure
viability and purity.
Antimicrobial Susceptibility
Determination
Susceptibility testing was performed by the agar dilution method
according to the CLSI M07-A9 standard with some modification
based on the characteristics of H. parasuis. A 2 µL H. parasuis
suspension (108 CFU/mL) was inoculated onto TSA-FCS-NAD
agar plates containing twofold dilutions (0.015∼32 µg/mL) of
tilmicosin (Dr. Ehrenstorfer Standards, Augsburg, Germany).
Plates were incubated at 37◦C in an atmosphere containing 5%
CO2 for 36 h. Enterococcus faecalis (ATCC 29212) was used as
the quality control (QC) strain to ensure the credibility of MICs
tested.
Definition of Wild Type Cutoff (COWT) or
Epidemiologic Cutoff (ECV)
A microorganism is defined as WT for a species by the absence
of resistance mechanisms to target drug (Turnidge et al., 2006;
Turnidge and Paterson, 2007). The ECV, or COWT is used to
separate bacterial populations on the basis of MIC distributions
(Turnidge and Paterson, 2007; Espinel-Ingroff et al., 2010;
Canton et al., 2012). Ideally, at least 95% of WT isolates should be
encompassed into the ECV (Pfaller et al., 2009, 2010, 2011). The
ECV was calculated following the method described by Turnidge
(Turnidge et al., 2006). Briefly, Normality testing of the WT
distribution was conducted with Sigmastat software v.3.5, non-
linear regression was used to fit log2-transformed MICs with
Graphpad Prism v.5.01, NORMINV and NORDIST functions
were employed to set the WT distribution cutoffs.
Determination of Possible Resistance
Mechanism
The molecular mechanism involved in macrolide resistance in
H. parasuis is unclear, however, mutations in the 23S rRNA that
is commonly associated with macrolide-resistance may occur in
H. parasuis. Therefore, PCR amplification (Hao et al., 2013) with
the primers 23S-F (5′-ACGGTCCTAAGGTAGCGAAAT-3′) and
23S-R (5′-CATCAAATGTTAAAGGGTGGTA-3′) was used to
screen mutations in the 23S rRNA gene in H. parasuis.
In vitro Time Killing Test
According to the determined MIC of H. parasuis SH0165, agar
plates were prepared with concentrations of tilmicosin (Dr.
Ehrenstorfer standards, Augsburg, Germany)) ranging from 1/4
to 32 MIC. A total of 0.1 mL of inoculum was plated and bacterial
counts were performed at 0, 1, 2, 4, 8, 12, and 24 h.
Animals
Fourteen 10-weeks-old healthy crossbred (Duroc × Large
white × Landrace) pigs weighing 28–33 kg were purchased
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from Huazhong Agricultural University pig breeding farm. Prior
to experiments, pigs were raised 7 days to acclimate. Two
pigs were used for establishment of high performance liquid
chromatography (HPLC) method, another 12 pigs were used for
pharmacokinetics (PK) study.
All the animal experiments were approved by the Animal
Ethics Committee of Huazhong Agricultural University (hzauch
2014-003) and the Animal Care Center, Hubei Science and
Technology Agency in China (SYXK 2013–0044). All efforts were
used to reduce the pain and adverse effect of the animals.
PK Study Design
The 12 pigs were randomly divided into two groups. Tilmicosin
was orally administrated to six pigs in each group at a single-dose
of 40 mg/kg/bw. This dose was designed based on the clinical
outcome of 400 mg/kg feed (about 40 mg/kg/bw) for treatment
of H. parasuis in pigs (MacInnes et al., 2003). In Group A, blood
(2 mL) samples from animals were obtained at 0, 0.5, 0.75, 1, 2,
3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h after administration. In
Group B, PELF samples were collected at 0, 0.5, 2, 4, 6, 8, 12, 24,
36, 48, 72, and 96 h post-drug administration.
Anesthesia Scheme and Bronchoaveolar
Lavage (BAL)
Atropine (0.05 mg/kg), ketamine (5 mg/kg), and propofol
(3 mg/kg) were given intramuscularly and intravenously 30 min
before drug administration.
Standardized BAL was performed as previously described
(Yamazaki et al., 2003; Choi et al., 2012; Lee et al., 2015), with
an electronic fiberoptic bronchoscope (Kangmei GU-180VET)
inserted in the right middle lung lobe. Then, 50 mL of normal
saline was instilled into the lobe, and was aspirated into a 50 mL
centrifugal tube after 20 s.
Specimen Handling
Plasma was separated from blood by centrifugation at 3000 × g
for 10 min and was kept at −70◦C until assay. The PELF was
centrifuged at 400 × g for 10 min and stored at −70◦C until
analysis.
Tilmicosin Assay Using High
Performance Liquid Chromatography
(HPLC)
Quantitation analysis of tilmicosin in PELF and plasma
were conducted using HPLC. A C18 reverse-phase column
(250 mm × 4.6 mm i.d., 5 µm; Agilent) was used to perform
HPLC at 30◦C. The detection wavelength was 285 nm. The
mobile phase consisted of 5 mM ammonium formate added with
0.1% formic acid (phase A) and acetonitrile (phase B; 73:27, v/v).
Plasma (0.5 mL) was extracted with dichloromethane (2.5 mL)
twice. After centrifugation, supernatant was evaporated and
resuspended in the mobile phase (0.5 mL). PELF (0.5 mL)
was extracted with acetonitrile (2 mL), and then centrifuged,
evaporated and resuspended in a same manner.
The limit of determination (LOD) was 0.02 µg/mL and
the limit of quantification (LOQ) was 0.05 µg/mL both in
plasma and PELF. Standard curves were linear from 0.05 to
10 µg/mL both in plasma (R2 = 0.9998) and PELF (R2 = 0.9999).
The inter-day variation for determination in plasma ranged
from 0.78 to 1.14% and PELF 0.14 to 0.78%, respectively. The
recovery of tilmicosin in plasma ranged from 93.67 ± 1.06%
to 97.16 ± 1.00% and in PELF from 98.49 ± 0.77 to
99.44± 014%.
Quantitation of PELF Volume
The urea dilution method was used to determine the
volume of PELF as described previously (Conte et al.,
2000a; Kiem and Schentag, 2007). The concentration of
urea in plasma and PELF were determined by the urease-
glutamate dehydrogenase enzymatic method with an automatic
biochemical analyzer (SYNCHRON CX4 PRO; Beckman) at
the National Reference Laboratory of Veterinary Drug Residues
(Wuhan, China).
Pharmacokinetics Analysis
Statistical analysis was conducted by using WinNonlin v.
5.2.1. Plasma concentration data was analyzed with a two-
compartment model and PELF non-compartment model
according to the characteristics of concentration-time data.
Monte Carlo Simulation and COPD
Crystal Ball v7.2.2 was used to perform Monte Carlo simulation.
The mean value and standard deviation of AUC24 of PELF were
embedded in the function. The distribution of pharmacokinetic
parameter AUC24 was assumed to be log-normal. A total of 10000
subjects were simulated.
The PK/PD target was evaluated (Andes et al., 2004).
Conservative value (AUC/MIC= 30) was selected to calculate the
probability of target attainment (PTA). COPD was defined as the
MIC at which the PTA was ≥90%.
RESULTS
Wild-Type (WT) MIC Distribution
All presumptive H. parasuis isolates were confirmed by PCR-
based method. The MIC for Enterococcus faecalis (ATCC 29212)
was 8 µg/mL, which was within the acceptable QC range
according to CLSI document M31-A3.
The WT MIC distribution for tilmicoin against H. parasuis
is shown in Figure 1. The tilmicosin MIC ranged from 0.06
to 16 µg/mL. The distribution of each MIC (0.06, 0.125,0.25,
0.5, 1, 2, 4, 8, and 16 µg/mL) among tested isolates was as
follows: 0.06 µg/mL (1.94%), 0.12 µg/mL (4.85%), 0.25 µg/mL
(19.42%), 0.5 µg/mL (15.53%), 1 µg/mL (28.16%), 2 µg/mL
(15.53%), 4 µg/mL (10.68%), 8 µg/mL (2.91%), and 16 µg/mL
(0.97%). The MIC50 and MIC90 were 1 and 4 µg/mL,
respectively.
The Epidemiologic Cutoff Value (ECV)
Despite a lower prevalence at the MIC of 0.5 µg/mL, cumulative
counts of MIC data were found to match a good-shape
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FIGURE 1 | Primary MIC distribution of tilmicosin against 103
Haemophilus parasuis isolates.
FIGURE 2 | Cumulative MIC distribution of tilmicosin against
H. parasuis after non-linear regression.
normal distribution by use of normality test (P = 0.200)
as shown in Figure 2. The optimum MIC range (0.015–
16 µg/mL) was obtained using non-linear regression (Table 1).
In addition, this range was further corrected to 0.06–16 µg/mL
by employing the NORMINV function. The probabilites of
an isolate MIC value higher than the high cutoff (0.18%)
and lower than the low cutoff (0.07%) were estimated using
NORMDIST function. As the result, the ECV was defined
as 16 µg/mL, which encompassed 100% of the WT isolates
(Table 1).
After PCR amplification and DNA sequencing, no 23S rRNA
gene mutations associated with macrolide resistance were found
among all of the tested H. parasuis isolates. Therefore, all isolates
were assumed to be WT strains.
In vitro Time Kill Curve
As displayed in Figure 3, the lower concentrations (≤MIC) of
tilmicosin exhibited similar antimicrobial activity to H. parasuis.
However, when tilmicosin concentrations were higher than
MIC, the bacteriostatic efficiency gradually strengthened due to
increased drug concentration. Therefore, the in vitro time kill
curve showed that activity of tilmicosin against H. parasuis was
concentration-dependent. TA
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FIGURE 3 | The in vitro time killing curve of tilmicosin against
H. parasuis. Fixed concentration (106CFU/mL) of H. parasuis was incubated
with different concentration of tilmicosin (1/4 MIC, 1/2 MIC, . . .. . ., 32 MIC). The
X-axis was the different time point and the Y-axis was log10 transformed
number of H. parasuis.
FIGURE 4 | Concentration-time curve of tilmicosin in plasma and in
epithelial lining fluid (ELF) after oral administration at a single dose of
40 mg/kg to pigs (n = 6). The concentration of tilmicosin in plasma was
determined at 0, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 h
after drug administration. The concentration of tilmicosin in ELF was detected
at 0, 0.5, 2, 4, 6, 8, 12, 24, 36, 48, 72, and 96 h post-drug administration.
Pharmacokinetic Characteristics of
Tilmicosin in Plasma
No serious adverse influences were observed after oral
administration of tilmicosin. The concentration of tilmicosin
in plasma was reduced below the LOQ after 72 h. A two-
compartment model was used for model fitting from 0 to
72 h. The concentration and time profiles are illustrated in
Figure 4. Pharmacokinetic parameters of tilmicosin in plasma
were calculated by model analysis conducted by WinNonlin
v. 5.2.1. As shown in Table 2, the time to reach to maximum
concentration (Tmax), the peak drug concentration (Cmax), and
the area under the curve at 24 h (AUC24) were 3.52 ± 0.34 h,
1.57± 0.46 µg/mL, and 20.13± 5.26 µg. h/mL, respectively. The
mean residence time (MRT) was 16.45± 1.67 h. The intercept for
the distribution phase (A) and for the elimination phase (B) were
TABLE 2 | Pharmacokinetic parameters in plasma and ELF after oral
administration of tilmicosin at a single dose of 40 mg/kg.bw.
Parameters Mean ± SD values
Plasma ELF
AUC24 (µg.h/mL) 20.13 ± 5.26 74.41 ± 17.98
Tmax (h) 3.52 ± 0.34 40.80 ± 6.57
Cmax (µg/mL) 1.57 ± 0.46 5.36 ± 0.74
A (µg/mL) 2.67 ± 0.99
B (µg/mL) 0.09 ± 0.01
α (L/h) 0.11 ± 0.01
β (L/h) 0.002 ± 0.001
MRT (h) 16.45 ± 1.67 37.64 ± 1.86
AUC24 was area under the curve from 0 to 24 h; Tmax was time to peak
concentration. Cmax was peak concentration; A was intercept for the distribution
phase; B was intercept for the elimination phase; α was distribution rate constant.
β was elimination rate constant; MRT was mean residence time.
2.67± 0.99 µg/mL and 0.09± 0.01 µg/mL. The distribution rate
constant (α) and elimination rate constant (β) were 0.11 ± 0.01
L/h and 0.002± 0.001 L/h.
Pharmacokinetic Characteristics of
Tilmicosin in PELF
After drug administration, the tilmicosin concentration in
PELF reached to a higher level at 3 h and kept at that
level until 96 h. A non-compartment model was selected to
analyze the drug concentration and time characteristics for PELF
samples. The pharmacokinetic parameters for PELF samples are
summarized in Table 2. The values (mean ± SD) of Tmax, Cmax,
AUC24, and MRT were 40.80 ± 6.57 h, 5.36 ± 0.74 µg/Ml,
74.41± 17.98 µg.h/mL, and 37.64± 1.86 h, respectively.
Comparison of Pharmacokinetics in
Plasma and PELF
The concentration-time curves both in plasma and in PELF after
oral administration of tilmicosin at a single dose of 40 mg/kg/bw
are shown in Figure 4. The drug concentration in plasma and in
PELF was lower than 2 µg/mL during 0∼4 h. The concentration
of tilmicosin in plasma rapidly decreased from 1.36 µg/mL at 6 h
to 0.11 µg/mL at 72 h. In contrast, the drug concentration in
PELF remained more stable, as values were higher than 4 µg/mL
from 6 to 48 h and then showed a rapid decrease from 4.72µg/mL
at 48 h to 0.68 µg/mL at 96 h. Significant differences were
observed between drug concentrations in plasma and in PELF.
It was noteworthy that the drug concentration in PELF at 48 h
reached 4.72 ± 0.44 µg/mL, which was more than 40 times of
that (0.11 ± 0.03 µg/mL) detected in plasma. Both the values for
Cmax and AUC24 in PELF were obviously higher than those in
plasma (Table 2).
Monte Carlo Simulation and COPD
As presented in Table 3, 10,000 subjects were modeled by
employing Monte Carlo simulation. The PTA under different WT
MICs was calculated. The PTA achieved to 100% when MIC value
of 1 µg/mL was employed. However, the PTA was merely 76%
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TABLE 3 | The AUC/MIC value calculated by Monte Carlo simulation and
the accumulated probability of target attainment (PTA) of the target
AUC/MIC (≥30) at specific MIC breakpoints.
AUC24
(µg.h/mL)
MIC (µg/mL)
0.5 1 2 4 8
47 94 47 24 12 6
94 188 94 47 24 12
69 138 69 35 17 9
76 152 76 38 19 10
63 126 63 32 16 8
87 174 87 44 22 11
. . . . . . . . . . . . . . . . . .
PTA (%) 100 100 76 1 0
(far below 90%) under the MIC value of 2 µg/mL. Consequently,
the COPD was defined as 1 µg/mL.
DISCUSSION
Temporal and geographic differences could be frequently found
on the prevalence of resistance. For instance, H. parasuis isolates
from Denmark exhibited higher MIC90 to tilmicosin than those
isolated from Czech Republic (8 µg/mL vs. 2 µg/mL; Aarestrup
et al., 2004; Nedbalcová and Kucˇerová, 2013). In our study, 103
H. parasuis isolates were collected in 2014 and antimicrobial
susceptibility tests were performed using the agar dilution
method according to CLSI documents. The MIC90 (4 µg/mL) of
the 103 H. parasuis isolates was higher than that (2 µg/mL) of
strains isolated by Zhou et al. (2010).
Wild type isolates do not harbor any acquired mutational
resistance mechanisms. Hence, resistance markers specific for
a microorganism-drug combination should be determined
(Meletiadis et al., 2012). However, no mutations associated with
tilmicosin resistance have been confirmed in H. parasuis isolates
so far. The mutations associated with macrolide resistance in the
target gene of 23S rRNA did not occur in our H. parasuis isolates.
Conservatively, all H. parasuis isolates used in this study could be
considered WT strains.
The bactericidal characteristic of an antibiotic is closely
dependent on the organism-drug combination. The same drug
is likely to show distinct bactericidal features to different
bacterial strains. Most macrolide drugs exhibited time-dependent
antibacterial activity and two parameters (T > MIC and
AUC/MIC) were generally used for PK/PD modeling (Owens
and Ambrose, 2007). However, the effect of tilmicosin against
H. parasuis was concentration-dependent, according to the result
of the in vitro time kill test.
In previous reports, the drug concentrations at the infection
site were highly correlated to that in blood (Craig, 1998).
However, as macrolide drugs may accumulate in respiratory
organs, the concentrations of macrolides at the infection site were
undoubtedly better to predict the clinical outcome. Although
several intrapulmonary pharmacokinetic studies have been
conducted using BAL in humans (Conte et al., 2000a,b, 2005;
Heng et al., 2013), the BAL technique was still only limitedly
applied to establish intrapulmonary pharmacokinetic models
among mammal animals (Womble et al., 2007; Villarino et al.,
2013). Those intrapulmonary pharmacokinetics experiments
using BAL technique were normally designed for long term
studies with long sampling intervals. In our study, the PK data
of tilmicosin in PELF in pigs were obtained for the first time by
use of the BAL technique and intrapulmonary model on the basis
of our modified anesthesia method.
Although, the preparation methods for extraction of
tilmicosin from plasma were available in previous studies,
the extraction procedures were complex (Modric et al., 1998;
Stobba-Wiley et al., 2000). To simplify the extraction procedure,
we tested diverse chemical materials (acetonitrile, methyl
alcohol, dichloromethane and trichloromethane) and found
that dichloromethane was the optimum reagent for tilmicosin
extraction. Selection of the mobile phase was important for
HPLC methods. Complex chemical compositions had been
required for use in the mobile phase of HPLC for detecting
tilmicosin in previous studies (Shen et al., 2005; Abu-Basha
et al., 2007; Herrera et al., 2007). To improve the efficiency of
the HPLC method, we tried different mobile phases and found
that a mobile phase with simple composition (5 mM ammonium
formate: acetonitrile, 73:27, v/v) could satisfy requirements for
HPLC analysis of tilmicosin in plasma and in PELF.
Drug concentrations in PELF have been positively related
to antibiotic activity for treatment of intrapulmonary infections
(Kiem and Schentag, 2007). Previous study found that alveolar
macrophages with high concentrations of macrolide drugs could
migrate into the alveolar space when organisms or dust intrude
(Gladue et al., 1989). This is why we chose to establish our
intrapulmonary model in healthy subjects rather than diseased
animals, as the latter may influence the stability of the model.
Additionally, drug concentrations in PELF in healthy animals
should have more clinical relevance compared to that taken from
blood in diseased animals.
Pharmacokinetics of tilmicosin in the plasma of cattle, sheep,
swine and chicken have been previously described (Modric
et al., 1998; Shen et al., 2005; Abu-Basha et al., 2007). The
intrapulmonary pharmacokinetics of tilmicosin in swine was
reported in the present study for the first time. The plasma
pharmacokinetic data in this study was similar to what was
reported by Shen et al. (2005). Interestingly, the concentration
in PELF reached the peak value at 48 h, which was significantly
later than what was detected in plasma. This may because
macrolide drugs can accumulate and persist in respiratory
tissues for extended periods (Villarino and Martin-Jimenez,
2013).
The COPD (1 µg/mL) was lower than the ECV (16 µg/mL)
established in this study. The reasons may be: (1) the ECV
was overestimated because of existing, but currently unknown,
resistance mechanisms; or (2) the sample size in this study
was not enough to ensure definite results. Compared to the
breakpoint of tilmicosin against A. pleuropneumoniae and
P. multocida (16 µg/mL), the ECV for H. parasuis seemed
reasonable to be used as the final breakpoint of tilmicosin against
H. parasuis in pigs.
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